United States: Capitol Hill Update

New Bill Targets Drug Prices

Bipartisan legislation introduced in the Senate last week would require pharmaceutical manufacturers to alert the U.S. Department of Health and Human Services (HHS) before increasing prices more than 10 percent, continuing congressional pressure on the industry over drug pricing. The bill's authors – including Sen. John McCain, (R-AZ) – say it would bring needed transparency to the industry's pricing practices. The legislation also would require companies to certify to HHS the drug's manufacturing, research, and marketing costs, and net profits. The McCain legislation will not become law and likely won't receive even a committee hearing in Congress this year. Still, it's another indication of the bipartisan political sensitivity around drug prices; McCain is seeking re-election in November.

House to Vote on Long-Term Care Hospital Payments

The House this week is scheduled to consider legislation that would provide regulatory relief to several categories of long-term care hospitals, including easing the so-called "25 percent rule" that prohibits full reimbursement if 25 percent of a hospital's annual Medicare patient population comes from only one acute-care hospital. The legislation would temporarily reinstate the 50 percent threshold that was in place before July 1. It would also provide targeted relief from the site-neutral payment policy enacted as part of a 2013 law for four specific long-term hospital groups.

House Bill to Aid Critical Access Hospitals

The House on Monday is scheduled to vote on legislation that would provide regulatory relief for critical access hospitals by temporarily barring HHS from enforcing the physician supervision requirement. Although a rule by the Centers for Medicare and Medicaid Services (CMS) – twice blocked by Congress – requires that outpatient services be provided under the direct supervision of a physician, some rural and critical access hospitals say it reduces beneficiary access to services in areas where the number of physicians is limited. The legislation was introduced by Rep. Lynn Jenkins, (R-KS).

'Cures' Vote Not Expected This Week

House Energy and Commerce Committee Chairman Fred Upton, (R-MI) has been frenetically working to bring even a slimmed-down version of his legislation to the House floor this month for a vote. But disagreements over policy, new funding levels for the National Institutes of Health and corresponding offsets targeted at the pharmaceutical industry continue to stymie the "21st Century Cures" bill. The committee has been pushing offsets, including prohibiting drug patent settlements (pay-for-delay), potentially with some clawback features; lowering payments for home infusion drugs under the Medicare Part B durable medical equipment (DME) benefit to average sales price; and providing a generic drug applicant a new right to sue in federal court to secure a branded sample subject to a REMS (Risk Evaluation and Management Strategy) to conduct bioequivalence studies. Even if the House were to act this week, the Senate won't consider the bill until after the November elections.

Woodcock to Testify Before Senate Panel

Dr. Janet Woodcock, the director of the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research, will testify this week before the Senate Appropriations' FDA Subcommittee, which is continuing Congress' focus on drug prices. The subcommittee, which is chaired by Sen. Pat Roberts, (R-KS), wants to examine the FDA's role in promoting generic drug applications. Woodcock is expected to be criticized over the EpiPen and the agency's failure to approve multiple generics to ensure one company doesn't monopolize a market.

Mylan CEO to Testify

Mylan CEO Heather Bresch will testify Wednesday before the House Oversight and Government Reform Committee about her company's decision to raise prices for EpiPen. Republicans and Democrats on the committee have criticized the price increases. Reps. Jason Chaffetz, (R-UT) and Elijah Cummings, (D-MD) also said they will examine how to establish more competition for EpiPen as well as speeding the FDA's approval of generics. Also testifying is Douglas Throckmorton, deputy director of the FDA's Center for Drug Evaluation and Research. Meanwhile, Chairman Upton wrote to the HHS inspector general demanding an investigation into whether CMS is properly overseeing the program that requires drug makers to pay rebates in exchange for having their products covered by Medicaid. Upton singled out Mylan and asked whether the company had paid required rebates for EpiPen.

House Panel to Vote on Health Bills

The House Energy and Commerce Committee on Tuesday will vote on a series of mostly bipartisan healthcare bills, including legislation that would extend the authority of paramedics and other emergency medical services professionals to administer controlled substances to patients.

Other bills include:

  • Establishing a National Clinical Care Commission to evaluate and recommend solutions for better coordination and use of federal programs for people with diabetes and related metabolic syndromes and disorders;
  • Increasing data collection by HHS to help place maternal health professionals in more appropriate geographic regions and address health professional shortages through their existing participation in the National Health Service Corps;
  • Awarding grants to initiate and sustain mental health awareness training programs; and
  • Reauthorizing grants and scholarships for graduate and undergraduate nursing education.

Meanwhile, the committee's Oversight and Investigations Subcommittee will hold a hearing Friday on bioresearch labs. The panel has held hearings on shipments of live anthrax from federal labs at the Centers for Disease Control and an Army lab.

Senate Panel to Focus Diagnostic Tests

The Senate Committee on Health, Education, Labor and Pensions (HELP) will hold a hearing on Tuesday to address the regulation of laboratory-developed tests. Witnesses include Dr. David Klimstra of Memorial Sloan Kettering Cancer Center; Brad Spring of BD Life Sciences; Jeff Allen of Friends of Cancer Research; and Karen Kaul, chairwoman of the Pathology and Laboratory Medicine Department at NorthShore University HealthSystem. The committee also will discuss legislation introduced by Sen. Orrin Hatch, (R-UT) that would promote collaboration among doctors through technology designed to improve health outcomes.

CMS Likely to Meet MACRA Deadline

CMS last week submitted to the White House for final review its proposal to implement a new Medicare reimbursement system for physicians and other Part B clinicians, signaling the agency is likely to meet a Nov. 1 statutory deadline to publicly release a final rule. Congressional leaders in both parties have called on CMS to allow for flexibility for physician offices to meet the expected Jan. 1 reporting deadline for the Merit-Based Incentive Payment System. CMS did announce earlier this month that it would offer some flexibility in how doctors submit data for the quality reporting program. Congress is likely to hold hearings next year to evaluate how CMS is implementing the payment system and how well doctors are meeting reporting requirements and deadlines.

Lawmaker Pushes Bill to Overturn Device Preemption

Rep. Mike Fitzpatrick, (R-PA) last week advocated for his legislation that would overturn a 2008 Supreme Court decision affirming preemption protections for medical technology that undergoes the FDA's most-stringent review process. Fitzpatrick met last week with several Pennsylvania constituents and touted his legislation, which was introduced in June. The bill, which has only one co-sponsor, is not expected to receive serious consideration in Congress. Fitzpatrick has long been an industry critic and champion of legislation backed by trial lawyers against device manufacturers. Fitzpatrick is not seeking re-election in November.

Democrats Push Back on Part B Demo

Nine House Democrats last week urged CMS to scale back its controversial five-year Medicare Part B prescription drug pilot program. As the Obama administration enters its final months, it is expected to release the rule to authorize the demonstration testing competing approaches for physician payments for office-administered drugs. Lawmakers in both parties have criticized the pilot's scope and lack of input from stakeholders. Some in Congress want to approve legislation in the post-election lame duck voting session to block the Part B rule, which some lawmakers and stakeholders fear is a precursor to a similar far-reaching demonstration for Part D drugs.

Drug Industry Reaches Biosimilars Agreement

The new Congress sworn in next January will begin review of a series of user fee agreements after the pharmaceutical industry and FDA reached an agreement over agency user fees for biosimilars. The agreement for alternatives to branded biologics will be packaged with other user fee renewals for branded and generic drugs and medical technology into comprehensive legislation that Congress will consider in 2017, before the current user fees expire next September. Lawmakers are unlikely to change the industry-FDA deals but could add other policies related to regulatory approvals.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.